DoseOptics
DoseOptics is a Dartmouth spinoff that builds FDA-cleared BeamSite Cherenkov imaging cameras enabling real-time, on-patient visualization of radiation delivery in hospital radiation oncology departments, with a co-developed DoseRT offering distributed globally via Vision RT.
- Company typePrivate
- Founded2015
- HeadquartersLebanon, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What DoseOptics does
DoseOptics, LLC is a Lebanon, New Hampshire-based medical device company founded in 2015 as a spinoff of Dartmouth College to commercialize Cherenkov imaging technology for safer radiotherapy. The company's flagship product, BeamSite®, is an FDA 510(k)-cleared camera and software system that captures the faint visible light (Cherenkov radiation) emitted by tissue during photon external beam radiotherapy, then synchronizes that imaging to the linear accelerator pulse at up to 400 Hz to deliver real-time, always-on visualization of the radiation beam directly on the patient. A research-oriented variant, BeamSite Research, serves academic and clinical research institutions, while a co-developed integrated offering, DoseRT™ powered by BeamSite®, combines DoseOptics' Cherenkov imaging with Vision RT Limited's AlignRT® Horizon surface-guided radiation therapy cameras to provide combined 3D surface and real-time beam visualization.
The company generates revenue through capital sale of BeamSite camera and software systems to hospital radiation oncology departments and cancer centers, supplemented by professional services for on-site survey, installation, and field service, and increasingly through OEM/channel supply into Vision RT's global sales channel for DoseRT. GTM is sales-led and demo-driven, with prospects routed via a Calendly 'Request a Meeting' funnel and supported by a US field-engineering team that travels up to 50% of the time. Customers are predominantly large hospital radiation oncology departments, with Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center publicly identified as the flagship first-in-world user; more than 50 peer-reviewed publications and a 2026 SPIE Prism Award finalist designation in Biophotonic Instruments underpin the clinical credibility proposition.
The company is privately held, early in US commercialization following its December 2020 FDA clearance, and is in active commercial scale-up mode, currently hiring a Sales Manager – Medical Device Sales and a field Engineer – Medical Devices to expand North American coverage. Historic funding has come almost entirely from NIH grants (an R01 from NIBIB in 2010–2014 and a series of NCI grants from 2015 onward, totaling roughly $3.4M in disclosed rounds in 2015 and 2016), with no disclosed venture equity rounds to date.
DoseOptics firmographics
Firmographics- Name
- DoseOptics
- Legal name
- DoseOptics, LLC
- Website
- https://doseoptics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DoseOptics is a Dartmouth spinoff that builds FDA-cleared BeamSite Cherenkov imaging cameras enabling real-time, on-patient visualization of radiation delivery in hospital radiation oncology departments, with a co-developed DoseRT offering distributed globally via Vision RT.
- Ownership category
- akta.pro rank
DoseOptics industry classification
Industry- Product category
- Radiation Oncology Medical Imaging
- NAICS
- Irradiation Apparatus Manufacturing (334517)
- SIC
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
- akta.pro secondary industry
- Radiation Dose Management & Analytics (HLACALAH)
Keywords
Where DoseOptics is headquartered
LocationHeadquarters
- HQ city
- Lebanon
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
DoseOptics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical imaging hardware sales (BeamSite systems): Primary revenue stream is sale of BeamSite camera and software systems (and the BeamSite Research variant) to hospitals and cancer centers. Capital medical device sales, typically a one-time hardware/license transaction per system installed. Customers are hospitals and radiation oncology departments; the company is in early commercialization following FDA 510(k) clearance (December 2020).
- Professional services: survey, installation, and field service: Engineer – Medical Devices role includes conducting facility surveys, installation per standard procedures, planned maintenance/upgrades, and reactive breakdown support (remote and on-site). These services are typically bundled with or follow hardware sales.
- Channel sales via Vision RT (DoseRT powered by BeamSite): Through the 2024 strategic partnership with Vision RT Limited, DoseOptics' Cherenkov imaging is bundled into the DoseRT solution alongside AlignRT Horizon SGRT cameras, leveraging Vision RT's global sales reach. Launched commercially in 2025; revenue mechanism likely involves OEM/licensing/component supply to Vision RT plus shared economics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise pricing; no public price list |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
DoseOptics product offering
Product offeringCore offering
DoseOptics designs, manufactures, and sells the BeamSite® Cherenkov imaging camera and software system, which provides real-time, always-on visualization of radiation beam delivery directly on the patient during photon external beam radiotherapy without adding ionizing dose, setup time, or workflow burden. The company also offers BeamSite Research, a research-grade variant, and DoseRT™ powered by BeamSite®, a co-developed integrated solution with Vision RT that combines Cherenkov imaging with surface-guided radiation therapy cameras.
Product overview
DoseOptics offers a portfolio of Cherenkov imaging products for radiation oncology centered on its FDA 510(k)-cleared BeamSite® clinical camera system, which captures real-time Cherenkov light from tissue during photon external beam radiotherapy. The core BeamSite product is complemented by BeamSite Research, a tripod-mountable, customizable research-grade version of the same imaging platform, and by DoseRT™ powered by BeamSite®, a co-developed integrated offering launched commercially in 2025 that pairs BeamSite Cherenkov imaging with Vision RT's AlignRT® Horizon SGRT cameras to provide both 3D surface positioning and real-time beam visualization in a single solution.
Differentiator
Problem solved
Functional benefit
Brands
- BeamSite: FDA 510(k)-cleared clinical camera system that captures Cherenkov light emitted during radiation therapy to provide real-time visualization of radiation delivery directly on the patient.
- BeamSite Research
- DoseRT (powered by BeamSite)
Products and services
- BeamSite® FDA 510(k)-cleared camera and software system that captures Cherenkov light emitted during radiation therapy to provide real-time, always-on visualization of the radiation beam directly on the patient during photon external beam radiotherapy. Adds no ionizing dose, setup time, or workflow burden; supports multi-camera full-body coverage, entry and exit beam visualization, and recorded anomalies for QA review. For hospital radiation oncology departments and cancer centers.
- BeamSite Research Research-grade radiotherapy verification camera and software system based on the BeamSite platform, designed for capturing real-time video of every radiation fraction. Features tripod or ceiling mounting, customizable acquisition settings, USB3 GenICam interface, 1600x1200 12-bit imaging at up to 60 FPS, and integration with treatment plan files, isocenter registration, and QA workflows. For universities and research hospitals conducting radiotherapy imaging research.
- DoseRT™ powered by BeamSite® Integrated radiation therapy monitoring solution co-developed with Vision RT Limited that combines DoseOptics' BeamSite Cherenkov imaging with Vision RT's AlignRT® Horizon surface-guided radiation therapy (SGRT) cameras to visualize both the 3D patient surface and the radiation beam delivery in real time. For hospital and cancer center radiation oncology departments seeking combined surface-position and beam-visualization monitoring.
Quantifiable outcome
- Improper patient positioning identified in 7 of 10 treatment fractions in a published retrospective evaluation
- +4 more outcomes
Companies that use DoseOptics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
DoseOptics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability5 records
Feature6 records
DoseOptics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Vision RT LimitedflagshipFollowing several years of collaboration, DoseOptics and Vision RT Limited entered a strategic partnership through which a fully integrated offering combining Cherenkov imaging (BeamSite) with AlignRT Horizon SGRT cameras is delivered as DoseRT powered by BeamSite. DoseRT underwent extensive clinical testing and launched commercially in 2025. The agreement combines DoseOptics' Cherenkov imaging R&D leadership with Vision RT's SGRT leadership, product execution capability, and global sales reach, with continued co-development on additional workflow solutions.
- Dartmouth College (Thayer School of Engineering / Geisel School of Medicine / Norris Cotton Cancer Center)coreDoseOptics is a spinoff from Dartmouth, founded to translate Cherenkov imaging research from the Thayer School of Engineering into a commercial clinical product. Co-founder Dr. Brian Pogue holds the Robert A. Pritzker Chair in Biomedical Engineering at Dartmouth and continues as Professor of Engineering Science and Professor of Surgery. Discovery, preclinical development, and early clinical testing were performed at Dartmouth's Thayer School and the Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center.
- Norris Cotton Cancer Center (NCCC) at Dartmouth-Hitchcock Medical CentercoreSite of preclinical and clinical testing of BeamSite; the first cancer center in the world to regularly use DoseOptics BeamSite camera systems across its Radiation Oncology Department. Provided published clinical evidence (e.g., Jarvis et al., Red Journal 2021; Alexander et al. 2021) supporting BeamSite's value for incident detection.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
DoseOptics competitors and assessment
Company assessmentBroad incumbents
- Varian Medical Systems (Siemens Healthineers): Varian is the largest LINAC and oncology informatics vendor (TrueBeam, Ethos, ARIA). Its EPID-based dosimetry, in-room imaging, and AI-driven HyperSight/Adaptive workflows target similar hospital radiation oncology QA budgets as BeamSite.
- Brainlab: Brainlab offers ExacTrac patient positioning and surface-guided imaging widely used in SRS/SBRT and LINAC environments. It competes for the same radiation oncology QA capital dollars that DoseOptics targets with BeamSite.
- IBA (Ion Beam Applications): IBA is a leading proton therapy vendor. Although BeamSite is not cleared for protons today, IBA's installed base represents a logical expansion adjacency if DoseOptics pursues future proton clearances.
- Accuray Incorporated: Accuray (CyberKnife, TomoTherapy) sells specialty radiation therapy systems with proprietary imaging and QA. It addresses the same hospital and freestanding radiation oncology buyer base as DoseOptics.
- Elekta AB: Elekta is a major radiation therapy and radiosurgery incumbent (LINACs, Leksell Gamma Knife, Versa HD). Its installed base, treatment planning, and emerging software/QA portfolio overlap with DoseOptics' hospital radiation oncology customers and could bundle competing QA tools.
Direct peers
- Vision RT Limited: Vision RT is the market-leading surface-guided radiation therapy (SGRT) vendor, whose AlignRT platform is the natural complement to BeamSite. The two companies co-developed DoseRT powered by BeamSite (launched 2025), making Vision RT simultaneously DoseOptics' strategic channel partner and the closest direct peer in on-patient / surface-based radiotherapy imaging.
- C-Rad AB: C-Rad develops surface-guided imaging and patient positioning systems for radiation therapy (Catalyst, Sentinel, Geminy). It competes head-to-head with AlignRT and increasingly in the real-time treatment monitoring category that DoseOptics addresses with BeamSite.
Emerging players
- MedPhoton: MedPhoton develops in-room CT and imaging systems for radiation therapy. It addresses adjacent in-room imaging needs for the same LINAC bunker customer DoseOptics serves with BeamSite.
- OSL - Optical Surface Localization (part of DJO/Enovis): OSL provides optical surface localization systems for patient setup and monitoring in radiation therapy, overlapping with the SGRT/real-time monitoring category in which DoseOptics competes.
- Standard Imaging: Standard Imaging supplies QA phantoms, detectors, and software for radiation oncology. Its QA customer base and tools overlap with the QA workflow DoseOptics addresses with BeamSite imaging.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
DoseOptics social profiles
Digital presenceDoseOptics compliance and trust
Trust signalCompliance1 record
DoseOptics financial estimates
Financial estimateRevenue estimate
Valuation estimate
DoseOptics leadership team
Management profileNumber of profiles
Profiles4 records
DoseOptics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DoseOptics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DoseOptics
What does DoseOptics do?
DoseOptics designs, manufactures, and sells the BeamSite® Cherenkov imaging camera and software system, which provides real-time, always-on visualization of radiation beam delivery directly on the patient during photon external beam radiotherapy without adding ionizing dose, setup time, or workflow burden. The company also offers BeamSite Research, a research-grade variant, and DoseRT™ powered by BeamSite®, a co-developed integrated solution with Vision RT that combines Cherenkov imaging with surface-guided radiation therapy cameras.
Is DoseOptics a public or private company?
DoseOptics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DoseOptics founded?
DoseOptics was founded in 2015. It employs 1 to 10 people.
Where is DoseOptics based?
DoseOptics is headquartered in Lebanon, United States, in the North America region.
How does DoseOptics make money?
Three revenue lines are on record. Medical imaging hardware sales (BeamSite systems) is the primary driver. The others are professional services: survey, installation, and field service and channel sales via Vision RT (DoseRT powered by BeamSite).
Who are DoseOptics's main competitors?
Broad incumbents on record are Varian Medical Systems (Siemens Healthineers), Brainlab, IBA (Ion Beam Applications), Accuray Incorporated and Elekta AB. Direct peers are Vision RT Limited and C-Rad AB. Emerging players are MedPhoton, OSL - Optical Surface Localization (part of DJO/Enovis) and Standard Imaging.
Does DoseOptics have an API?
No public API is recorded for DoseOptics.
What industry is DoseOptics in?
DoseOptics's product category is Radiation Oncology Medical Imaging. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLACALAH, Radiation Dose Management & Analytics. Its NAICS code is 334517 and its SIC code is 3844.